Navigation Links
Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares
Date:10/20/2011

NATICK, Mass., Oct. 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces financial results for the third quarter ended September 30, 2011, as well as updated sales and earnings per share (EPS) guidance for the fourth quarter and full year 2011. 

Third quarter and other highlights:

  • Achieved sales of $1.874 billion; and reported GAAP earnings of $0.09 per share and adjusted EPS of $0.15, both exceeding previous guidance

  • Invested $192 million to purchase 30 million shares under the Company's estimated $1.25 billion combined share repurchase authorizations

  • Increased constant currency worldwide sales of Endoscopy by 6 percent, Peripheral Interventions by 4 percent and Neuromodulation by 6 percent, all on the continued strength of new products

  • Achieved double digit sales growth in the three largest emerging markets of Brazil, India and China

  • Maintained substantial leadership position in the global drug-eluting stent market with 36 percent share worldwide and U.S. share of 49 percent

  • Generated strong operating cash flow of $366 million, ending the quarter with $276 million of cash on hand

  • Promoted Hank Kucheman to Chief Executive Officer and welcomed Mike Mahoney as President

  • "Boston Scientific's earnings performance remains strong, despite very challenging global economic and end-market conditions that adversely impacted revenue," stated Hank Kucheman, Chief Executive Officer of Boston Scientific Corporation.  "The execution of the Company's POWER strategy is the right top priority for the entire leadership team."Sales for the third quarter of 2011 were $1.874 billion, as compared to sales of $1.916 billion for the third quarter of 2010, a decrease of 2 percent.  Excluding the impact of changes in foreign currency exchange rates and sales
    '/>"/>

    SOURCE Boston Scientific Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

    Related medicine technology :

    1. Boston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent
    2. Boston Scientific Launches Promus Element™ Stent System In China
    3. Boston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate
    4. Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results
    5. COPAN WASP® Lands at Prestigious Boston Medical Center
    6. Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial
    7. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent
    8. Bluestar Silicones to Present Antimicrobial Silicones at Medical Silicones Conference in Boston
    9. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
    10. Boston Scientific Launches Coyote™ Balloon Catheter
    11. Boston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... -- Stryker Orthopaedics, the Official Joint Replacement Products of ... its debut year of the relationship at the Charles ... This marks the eleventh tournament stop along both ... has activated on-site with the "Stryker Mobility Zone" – ... importance of joint health.  The Stryker ...
    (Date:10/30/2014)... Calif. , Oct. 30, 2014  Electronic ... dramatically as a result of government initiatives and ... - healthcare providers have invested over the past ... heart of health IT, and U.S. clinicians use ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
    (Date:10/30/2014)... United Kingdom , Oct. 30, 2014 ... (Nasdaq: CBRX ) and Maryland ... drug developers with improved efficiency during clinical development that ... Diego next week. This partnership ... technologies platform, which it launched earlier this month. The ...
    Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
    ... International Partnership for Microbicides, issued the following statement ... and effectiveness study of BufferGel and PRO2000 (0.5 ... Microbicide Trials Network, a worldwide collaborative group funded ... released final results from its Phase II/IIb safety ...
    ... Only Approved Platelet Producer in Europe Represents New ... Feb. 6 Amgen (Nasdaq: AMGN ... has granted marketing authorisation for Nplate(R) (romiplostim) for ... thrombocytopenic purpura (ITP) patients who are refractory to ...
    Cached Medicine Technology:New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 2New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 3New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8
    (Date:10/30/2014)... Don Allred Insurance, a leading provider of home, ... Carolina residents, is excited to announce the Grand Opening ... The new branch has been up and running since ... facets of the insurance selection process from quote comparison ... couldn’t be happier with the timing of this Grand ...
    (Date:10/30/2014)... OR (PRWEB) October 30, 2014 Five ... firm Hodgkinson Street LLC announces new branding and ... Hodgkinson Street Mepham . After David Mepham’s promotion to ... their brand and website to include Mepham’s name and ... medical malpractice and mediation firm, the decision to implement ...
    (Date:10/30/2014)... N.C. (PRWEB) October 30, 2014 Paramount ... health care, is increasing efforts to help people save ... expenses continue to increase for prescription drugs in the ... valuable savings and resources to bridge the relationship between ... One of the biggest challenges people face today with ...
    (Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
    (Date:10/30/2014)... By Dennis Thompson ... -- The Ebola outbreak in Liberia -- one of three ... slowing, World Health Organization officials said Wednesday. Dr. Bruce ... in the number of burials in Liberia and no increase ... the global push to tame the epidemic may be making ...
    Breaking Medicine News(10 mins):Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
    ... the Stimulus Bil provide big boost for the conversion to electronic medical ... document scanning and document management systems. , ... Lakewood, CO (PRWEB) March ... to convert their paper records to digital files. Medical record scanning ...
    ... how precious it really is. 24k gold is a key ingredient in ... , ... York (PRWEB) March 6, 2009 -- While watching CNBC or other major news ... hear that it has kept a rather high value during this economic recession. ...
    ... continues to impose a huge burden on industrialized societies, ... absence. Annual costs related to back pain in the ... billion per year. , But a systematic review of ... February issue of The Spine Journal finds ...
    ... first, studies suggest , , THURSDAY, March 5 (HealthDay News) ... effective treatment is a short course of radiation therapy ... , Surgery is the standard treatment for rectal ... of cancer recurrence in the same area, according to ...
    ... (OTC Bulletin Board: POLGA ; OTC Bulletin Board: ... engineered materials, announced today it will release fourth quarter ... market on Wednesday, March 18, 2009. Company officials will ... at 10:00 a.m. EDT on Thursday, March 19, 2009. ...
    ... Dr. Steven St. Peter Named to Proteon Board of ... of the world,s largest life sciences-dedicated venture capital investors, ... a $38 million Series B equity financing of Proteon ... of MPM Capital, has been named to the Proteon ...
    Cached Medicine News:Health News:Stimulus Package Boosts Medical Document Scanning 2Health News:Gold Not Only Valuable, It's a Healthy Skin Care Ingredient 2Health News:Clinical trials' review finds only exercise to prevent low-back problems 2Health News:Rectal Cancer Outcomes Best With Short-Course Radiation 2Health News:Rectal Cancer Outcomes Best With Short-Course Radiation 3Health News:Polymer Group, Inc. Announces Fourth Quarter and Year-End 2008 Earnings Conference Call 2Health News:MPM Capital Leads Investment in Proteon Therapeutics 2
    Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....
    For the quantitative determination of iron, total iron-binding capacity in human serum....
    HDL Cholesterol, liquid....
    Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
    Medicine Products: